Virbac Animal Health is launching an initiative to highlight the prevalence of Benign Prostatic Hyperplasia (BPH), a condition suffered by more than 80% of entire male dogs over the age of five1.
The campaign will take place during November - or 'Movember' as it's called by the thousands of men who grow moustaches during the month to raise funds for male prostate and testicular cancer. Virbac says it hopes the campaign will remind dog owners that men are not the only ones to suffer from prostate disorders.
As part of the campaign, the company will be providing participating practices with promotional materials including free dog leads, owner educational and display materials, a press release for local media and practice educational materials.
Chris Geddes MRCVS, Virbac Product Manager, said: "It's estimated that 20% of the country's eight million dogs remain uncastrated throughout their lives. As dogs age, their prostates enlarge, eventually causing symptoms including constipation, lameness and difficulties in urination. However, most of the time clinical signs are absent or vague so diagnosing BPH can be a challenge."
According to Virbac, the traditional rectal examination technique can be an ordeal for both dog and clinician. It's also sometimes inaccurate even in experienced hands and is impossible in very small or large breeds. As a solution, the company has recently introduced Odelis CPSE, the first ELISA test to screen for, diagnose and monitor BPH, available from three UK diagnostic laboratories. The company says it's a cost-effective, precise and reliable alternative to rectal palpation. Virbac also offers Ypozane, a simple tablet treatment for BPH, which takes effect within a week and lasts for six months.
Chris added: "BPH is a serious threat to the health of entire dogs as they get older but owners are often unaware of the potentially serious health problems it can cause if left untreated.
"We hope that, by running our Prostate Awareness Campaign at a time when the media spotlight is already on the dangers of prostate cancer in men, we can help spread the message that owners should also be monitoring older dogs for signs of prostate disease.
"We're providing practices with all the materials they need to promote the campaign in their locality and hope that those getting involved will find it effective in terms of bringing dog-owning clients into the practice for advice on BPH."
For further information on the Prostate Awareness Campaign and to get your free pack please contact your Virbac Territory Manager or contact the company direct on 01359 243243.
Reference1. O'Shea J.D. Studies on the canine prostate gland: Factors influencing its size and weight. J. Comp. Pathol. 1962 72: 321-331.
Dechra Veterinary Products has launched Osphos, an intramuscular clodronic acid injection for the control of clinical signs associated with the bone resorptive processes of navicular syndrome in horses, the only such licensed product in the UK.
Dechra says it expects Osphos to change the way chronic lameness caused by navicular syndrome is tackled by equine vets.
According to the company, clinical trials of Osphos showed 74.7% of horses experienced improvement by at least one lameness grade at 56 days post treatment.
Dechra brand manager Emma Jennings said: "Osphos intramuscular injection contains the bisphosphonate clodronic acid which inhibits resorption in the navicular bone by binding to hydroxyapatite crystals and by direct cellular effects on osteoclasts.
"We are delighted with the results of the trials, which proved that Osphos is effective at 6 months post-treatment. We're looking forward to being able to support equine vets, vet nurses and practices by providing an intramuscular Clodronic acid injection for horses."
Dechra also says studies showed that mild transient colic was seen following just 1.6 per cent of treatments.
Osphos 60 mg/ml solution for injection for horses is available from September 2014.
Merial Animal Health has launched Locatim, an oral antibody supplement to aid calf scour management.
Manufactured from the colostrum of high health status cows that are hyper-immunised against E.coli, rotavirus and coronavirus, Locatim contains a guaranteed concentration of specific antibodies to enterotoxic E.coli F5 (K99).
Merial says that when given alongside the dam’s colostrum, Locatim provides enhanced protection against infection, reducing calf mortality due to neonatal diarrhoea caused by E.coli F5 (K99), and helping to protect calf health during the critical rearing period.
According to the company, a single 60ml oral dose provides direct transfer of these specific antibodies, giving local protection within the digestive tract and systemic protection following absorption through the intestinal mucosa.
For optimal absorption Locatim should be administered during the first four hours of life, but it can be given up to 12 hours after birth.
Locatim can be administered to every calf born during an outbreak of scour; at times of peak calving, when environmental challenge is high; or it can be used to enhance protection in individual calves identified as being at high risk of disease due to factors such as dystocia, weakness or the poor quality of the dam’s colostrum.
For information on purchasing stock contact your local Merial Animal Health territory manager.
Bravecto Triuno is approved for the treatment of tick and flea infestations in dogs (Ctenocephalides felis, C. canis, Dermacentor reticulatus, Ixodes hexagonus, Ixodes ricinus, and Rhipicephalus sanguineus).
It is also approved for the treatment of infections with roundworms (adult stages of Toxocara canis and Toxascaris leonina) and hookworms (L4, immature adult (L5), and adult stages of Ancylostoma caninum and Uncinaria stenocephala), for the prevention of heartworm disease (caused by Dirofilaria immitis), and for the prevention of angiostrongylosis (by reduction of the level of infection with immature adult (L5) and adult stages of Angiostrongylus vasorum).
Victoria Miles, UK Companion Animal Director, MSD Animal Health, said: “With this latest formulation of Bravecto, MSD Animal Health is giving veterinarians and dog owners a greater range of convenient options for protecting their dog year-round from parasites, and all from the same trusted Bravecto portfolio.”
She added: “We see Bravecto Triuno as a great option for puppies that require a monthly wormer on top of protection against fleas and ticks.
"This also gives flexibility later on for the dog to remain with the Bravecto brand but be swapped onto a longer-duration flea and tick product with a wormer administered according to a veterinarian’s risk-based assessment.”
Bravecto Triuno is available as a flavoured chewable tablet indicated for dogs and puppies from 8 weeks of age and at least 1.27 Kg body weight and can be administered monthly to dogs at risk of infestation by multiple types of internal and external parasites.
It contains three anti-parasitic ingredients including fluralaner, which provides activity against ticks and fleas, moxidectin, which provides systemic activity against non-intestinal worms, and pyrantel, which provides activity against intestinal worms.
https://www.noahcompendium.co.uk/?id=-488423
Boehringer Ingelheim Vetmedica has launched Pexion (imepitoin) a novel treatment for canine idiopathic epilepsy.
Canine epilepsy can affect up to 5% of dogs6. In most dogs diagnosed with idiopathic epilepsy no underlying cause for the seizures can be found. While the condition can affect any dog, it is more common in young (one to five year old), purebred dogs such as Labradors, Golden Retrievers, German Shepherds, Boxers, Vizlas, Beagles, English Springer Spaniels, Irish Setters, Poodles and Dachshunds.
Boehringer says Pexion has a highly targeted mode of action1-3 to suppress a dog's seizures. It starts to work within a few hours and reaches steady state within three days4,5. Boehringer claims this will make it easier to stabilise epileptic patients. It also says there is no evidence of hepatotoxicity or liver-associated enzyme elevation, so repeated blood tests for liver enzymes or therapeutic levels are no longer required.4,5
Pexion is available in 100 mg and 400 mg tablets. The tablets are white, scored and divisible in half. Both tablet strengths are available in 100 tablet packs from veterinary wholesalers.
Jemima Mead, brand manager at Boehringer said: "Pexion is a ground-breaking new product which gives vets a new first-line treatment option for dogs with idiopathic epilepsy, improving the lives of newly diagnosed epileptic dogs and their owners by reducing the number of seizures and their impact on the patient's life".
To support the launch of the new product, Boehringer hosted an epilepsy webinar presented by neurologist Dr Holger Volk DVM PhD DipECVN FHEA MRCVS, recognised RCVS and European Specialist in Veterinary Neurology. The webinar is now available on demand at www.bi-academy.co.uk.
For further information on Pexion visit www.pexion.co.uk, contact your local Boehringer Ingelheim territory manager or telephone +44 (0)1344 746959.
References
The BSAVA has launched a series of client information sheets for drugs commonly used off-label.
The information sheets were the brainchild of Professor Ian Ramsey, Editor-in-Chief of the BSAVA Small Animal Formulary. He said: "As a referral vet I write a lot of letters to owners and vets that include instructions about the drugs that I am prescribing or dispensing for a patient. Often these drugs are unusual or cytotoxic, and are very commonly only authorized for human patients. As Editor of the Formulary I am acutely aware of the responsibility that I have for making sure owners understand what these drugs are for and what the side effects might be."
The BSAVA says it hopes the leaflets will overcome the challenge veterinary surgeons have in remembering all the drug information that needs to be related to clients, and the problem of clients forgetting what they have been told verbally by the clinician during a consultation.
In addition to a basic introduction to the Prescribing Cascade, each of the client leaflets provides the following information:
The first batch of client information leaflets, which relate to the following medications prescribed for dogs and cats, is now available for members to download from the BSAVA website (http://www.bsava.com/):
Each of the leaflets has a space for veterinary practices to add their details before distributing them to their clients, and the BSAVA says more may be added during 2011.
Cryptisel is for use in reducing oocyst shedding in calves where diarrhoea caused by Cryptosporidium is a problem. After the presence of the causal organism has been established, Forte says Cryptisel can be used in all new-born calves to break the cycle of transmission and multiplication on-farm.
Dr John Henderson, Large Animal Product Manager with Forte Healthcare Ltd said: "Cryptisel will be a very useful medicine in the control of the most commonly-identified scour pathogen in the UK and Ireland. Used alongside the calf-rearing cornerstones of good colostrum management, hygiene, and biosecurity, Cryptisel will reduce production of Cryptosporidium oocysts and help limit spread of the disease among susceptible calves."
Cryptisel is a POM, available in 490ml and 980ml bottles. Both sizes come with a metered dosing pump for convenient administration.
For further information, contact your local Forte Territory Manager or email enquiries@fortehealthcare.com.
The MSD Animal Health Research Bursary for Veterinary Surgeons offers three awards, consisting of two ruminant bursaries and one companion animal bursary, of up to £4,000 each.
Each project should be completed within one to two years and the vet practitioner proposals will be judged by university academics to ensure independent assessment.
The companion animal research bursary will be assessed by the University of Nottingham Centre for Evidence-based Veterinary Medicine and the ruminant research bursary applications will be assessed by academic staff from the University of Bristol School of Veterinary Science.
Michelle Townley, veterinary advisor at MSD Animal Health (pictured right) said: "Our Vet Surgeon Research Bursaries have an important role to play in encouraging vet surgeons to continue to develop their research skills. New knowledge and good research skills form the life-blood of the industry so we’re keen to see proposals from both ruminant and companion animal practitioners. Being awarded a bursary has proved to be a career-changing experience for some participants so we’re keen to get as many applications as possible as part of our investment in the veterinary industry."
The deadline for entries is 30th November 2018. For more information, visit www.msdahresearchbursary.co.uk.
Trilotab is licensed for the treatment of pituitary-dependent hypercortisolism (PDH) caused by an adrenocorticotrophic hormone (ACTH)-secreting pituitary adenoma, which accounts for 85% of spontaneous cases of Cushing’s, and for the treatment of adreno-dependent hyperadrenocorticism (ADH) caused by a cortisol-secreting adrenocortical tumour (ACT), which accounts for the remaining 15% of spontaneous cases1.
The new tablet is divisible into halves and quarters to facilitate dose adjustment and make administration easier.
Divided tablets remain stable outside of the blister packaging until the next dose is due, thereby avoiding wastage.
Trilotab tablets are chewable and chicken-flavoured to help improve treatment compliance.
They contain hydrolysed chicken flavouring so they can be prescribed for pets allergic to chicken.
Trilotab is administered once daily with food with a starting dose of 2mg trilostane/kg bodyweight.
The new tabs are available in three presentations: 10mg, 30mg, and 60mg presentations, which Virbac says should help practices reduce their dispensary stockholding.
Andrew Connolly, Marketing Director – UK & Ireland at Virbac, said: ‘The complex nature of Cushing’s syndrome in dogs can make it a challenging condition to manage for both the clinician and the pet owner.
"With the requirement for lifelong treatment, it is our hope that Trilotab’s easy administration and simplified dosing protocols will genuinely help to improve the lives of dogs affected by the disease, whilst making the clinician and pet owner’s lives just a little bit easier too!"
Reference
Norbrook Laboratories has launched powder and paste versions of Noroquin - its glucosamine-based supplement range - for horses.
Noroquin contains the active ingredients glucosamine, chondrotin sulphate, manganese sulphate, zinc sulphate, absorbic acid and N-Acetyl-D-Glucosamine, designed to maintain healthy cartilage, promote joint management and keep horses mobile.
Michelle Jones, Brand Manager at Norbrook said: "In recent years, horses are increasingly competing longer which means maintaining the longevity of the horse is vitally important for long term success. 60% of lameness is related to osteoarthritis and is regarded as the major cause of disability in the athletic horse.
"With increasing reliability on nutritional supplements and concerns from horse owners about their aging horse, our Noroquin for Horses range can be offered as alternative to traditional pain management products indicated for musculoskeletal ailments or alongside them as a completely safe addition to a joint management programme."
Michelle added: "The Noroquin paste for horses is a highly palatable apple flavored paste that can be fed directly to the horse as a tasty treat and offers an alternative to traditional methods while the Noroquin powder for Horses is a highly palatable powder that can be mixed with food. The product is available in handy single-use sachets for accurate dosing and waterproof 1kg tubs."
Noroquin Powder and Paste for Horses joins the newly launched tasty tablets for dogs and cats and powder for cats in the Noroquin range. It is available from wholesalers.
Avacta has announced the launch of Natural VetCare Prescribed, a new range of veterinary exclusive nutraceutical skin and joint supplements.
The range is manufactured in the UK by Natural VetCare and includes four products in total.
Avacta’s commercial manager, Hayley Booth, said: "Cani Flex is designed to support the body’s anti-inflammatory response with a powerful antioxidant formula, which rebalances the system by addressing excess free-radical build up around the joint following injury or wear and tear. Cani Flex Senior also targets joint, heart and brain health and encourages increased activity.
"With allergies becoming more and more prolific, Cani Skin and Feli Skin target one of the most complex issues facing vets and pet owners in today’s environment. The formulations are designed to resolve the body's hypersensitivity by balancing the immune response.
Hayley added: "To ensure veterinary exclusivity, the unique dispensing method has been thoroughly researched and trialed. The easy-to-feed sprinkle capsules sold in individual gold foil pouches are not for sale individually, and boxes of pouches are available direct from veterinary wholesalers only."
For more information, visit avactaanimalhealth.com/NVCPrescribed, contact your Avacta territory manager or call customer services on 0800 8494 550.
In particular, the two companies are focussing on the production of more video content, with Improve filming and sharing high quality clinical demonstrations, and VetSurgeon.org sharing peer-reviewed community-driven content and knowledge.
VetSurgeon.org Publishing Editor Arlo Guthrie said: “This partnership, which brings together the clinical knowledge and infrastructure of the UK’s leading veterinary training provider with the country’s longest-established online veterinary communities, will substantially increase the amount of valuable content we can bring our members.
“Together, we're going to make VetSurgeon.org THE community for authoritative information and opinions."
To ask questions or discuss the new partnership, click here.
Matt has taken over as hospital director from David Walker, who has now moved to the role of referrals managing director in the south of the UK for Linnaeus.
Matt said: “I certainly have some big shoes to fill but working as clinical director alongside David was a great grounding and we work well together.
“Essentially, I was his running mate back then but now I am stepping up to take on the main role, with all the additional responsibilities it entails, and I’m determined to make it my own.
“I know I have the drive, the desire, the clarity of purpose and the dedication to succeed.
"I also know what an incredible operation I have inherited from David.
“One of the key things about Anderson Moores is that every member of the team works together in the same location to support every aspect of a pet’s treatment and recovery, so whatever service they may need is all available under the same roof.”
www.andersonmoores.com/homewww.zeropainphilosophy.com
The new, four storey, architecturally-designed clinic is full of natural light and includes calming and spacious staff breakout areas.
By combining a beautiful work environment with seamless technology, the company believes it can transform working conditions and job satisfaction for vet teams.
On the tech side, the Creature Comforts has created a proprietary app which allows triage to be handled online and for staff to work flexibly.
The company says the app also reduces the administrative burden, a contributory factor for staff burnout.
Creature Comforts says most clients subscribe at a cost of £20 per pet per month, giving them unlimited consultations, instant bookings and live chat via the app (as well as annual vaccinations and discounted routine treatments).
This should mean animals are seen more frequently, and conditions can be identified and treated earlier.
Memberships will be capped to control vet team caseload and to ensure a good customer experience.
The company is also addressing Competition and Markets Authority concerns, with prices for routine treatments listed on its website, upfront estimates for procedures, and a business model hinged on unlimited access to expertise (i.e. consultations, instant in-app bookings and live chat) at no extra cost for subscribed members.
Creature Comforts says its vet team benefits from a share of their clinic’s profits, above industry-standard pay, compensated overtime, a well-balanced staffing ratio, manageable working hours and scheduled breaks.
Dr Russell Welsh, COO and co-founder of Creature Comforts, said: “It’s an incredible feeling to see a plan come together in a sector that’s so ripe for transformation.
"We want to bring the passion, joy and fun back to our profession, and this is an opportunity to do things differently and vastly better, with a fresh and carefully-considered business model founded on the principles of health and happiness.
"This is vet care as it should be."
https://www.creaturecomforts.co.uk
Genitrix has extended its Dentagen dental care range with the addition of Dentagen Aqua, a water additive treatment to control plaque and prevent bad breath in cats and dogs.
Genitrix says the product offers a completely new approach to dental care for companion animals and is expected to prove particularly effective in treating cats which do not respond well to existing treatments, such as dental chews and tooth-brushing.
Dentagen Aqua is a palatable liquid which is added to a pet's drinking water on a daily basis. Its active principal is RF2, a plant extract. According to the company, RF2's ability to enable natural and healthy mouth bacteria to flourish while inhibiting the formation of plaque even at low concentrations has been demonstrated in extensive clinical trials. It operates as an 'anti-biofilm' treatment, modifying the growth of the membrane of oral bacteria to prevent them from producing plaque.
Dentagen Aqua is supplied in a 250 ml bottle costing £6.80. At the recommended dose of 5 ml per day, the bottle will provide 50 days' treatment for a cat or small dog.
In 2008, Genitrix launched the original Dentagen plaque protection system which consists of a unique RF2-impregnated wax provided to practices in a syringe to be applied to the gingival layer and the buccal area of teeth of dogs or cats at end of dental procedures. Dog owners can then maintain the protective coating by giving their pet Dentagen plaque prevention chews. The launch of Dentagen Aqua means that an equivalent solution is now available for cat owners or for dogs which don't eat chews.
With over 85% of dogs and cats over three years old suffering from some form of dental or gum disease, it's the most common health problem in these animals. The market for preventative dental healthcare supplements is estimated to be close to £1 million per annum.
Rob Watkins, Marketing Director at Genitrix, said: "Dentagen exceeded our expectations during its first year and has proved popular with both vets and dog owners. Given the vital importance of good dental health for dogs and cats, it seemed the logical next step to produce a water additive version to make the treatment easier for cat owners in particular."
Pet Anxiety Month aims to educate pet owners about the signs of anxiety in cats and dogs, help them identify the causes, and encourage them to take steps to support anxious pets (presumably by putting multiple diffusers in every home and blanketing large swathes of suburbia in a pea soup fog of pheromones).
Joking aside, the initiative comes on the back of the PDSA Animal Wellbeing report1 which revealed that over half of veterinary professionals think they've seen an increase in dog behavioural issues in the last two years, with over three-quarters of dog owners saying that they would like to change at least one behaviour displayed by their dog and nearly 90% of owners reporting that their cat is afraid of at least one thing.
To support the initiative, Ceva will be running a TV advertising campaign from 7 March until 21 April, which directly targets dog lovers during More4’s Crufts’ programmes (from 7 to 10 March).
The advertisements will also air on Channel 4, Channel 4 partner channels, Sky and Sky partner channels. Both advertisements are 30 seconds long.
Ceva is producing a marketing pack to raise awareness of Pet Anxiety Month containing eye-catching display materials and a social media toolkit.
Abigail King, Ceva's senior behaviour product manager, said: "More and more people are identifying anxiety and behavioural issues in their pets. Pet Anxiety Month will highlight signs of anxiety in cats and dogs that perhaps an owner is unaware of, help identify the problem and encourage changes both in and out of the home to make the household a happier place."
For further information, visit www.petanxiety.co.uk or Pet Anxiety Month on Instagram or Facebook.
Barclaycard has launched Paywag, a new NFC payment system for dogs.
Installed in a specially designed dog collar, the new system allows dogs to make payments up to £5.00 in value in selected pet stores and veterinary practices.
At this year’s event, sessions include ‘Backyard pigs – Notifiable Diseases and Zoonosis’, and a discussion on the role of paraprofessionals in the sector led by Simon Hall, APHA’s Director for EU Exit and Trade.
Drop-in Q&A sessions, workshops offering practical advice and guidance on the revalidation process and a strong focus on the Cymorth TB programme in Wales also feature.
The conference programme includes dedicated lecture streams aimed at large animal, small animal and equine practitioners and, with more than 8,000 OVs due to revalidate their qualifications in March 2019, Improve says lecture content has been tailored to cover areas of key relevance for them.
An exhibition of products and services for OV’s runs alongside the conference.
APHA’s recently appointed Veterinary Director, Dr Andrew Soldan (pictured right), said: "Having recently taken on the role of Veterinary Director for APHA, I am very much looking forward to meeting up with our OV’s and exploring some of the key challenges facing us all, as we seek to control animal disease threats at home and from abroad."
David Babington MRCVS, Business Development Director at Improve International, said: "This conference has established itself as an annual fixture in the OV diary and it remains the only event dedicated to their needs. This year’s packed programme will again highlight the growing importance of OV’s, particularly as we look ahead to the post-Brexit era."
For more information on the Official Veterinarian Conference and Exhibition or to register visit: www.officialvet.com
Katie, who works at Milbourn Equine, is now preparing with her horse Templar Justice, or TJ for short, to take part in what is widely acknowledged to be one of the world's most difficult equestrian events.
Last year, she competed at the Burghley Horse Trials and was voted "Amateur Rider of the Year" by Horse and Hound magazine.
Katie says she is determined to build on that success with a strong showing at Badminton: "The Burghley Horse Trials were amazing last year. I was so excited to be there and it went so well. To now be competing at Badminton will be an awesome experience.
"It’s one of only six 'five-star' equestrian events in the world and to compete there really is my dream come true."
As part of the programme, BEVA is giving the coaches workshops, discussion forums and online toolkits to develop their mentoring skills. Having been trained by a specialist mentoring professional, the coaches are then paired with recent graduates to give them guidance and support during the foundation years of their careers.
The project, called 'Leg Up', has been driven by BEVA President Renate Weller, and is being trialled over the next 12 months before being rolled out more widely.
Renate said: "All professionals, but especially new graduates need support in navigating their journey through their chosen career.
"With the veterinary industry’s rapidly changing landscape and rising concern around wellbeing, consistent support and guidance have never been more relevant."
Coaching is open to BEVA concessionary members who have graduated within the past three years. They will be able to self-select a preferred coach on a first come, first served basis from the Leg Up section of the BEVA website.
Renated added: "To date access to targeted careers support has most often depended on where you work and who you know. We hope the scheme will encourage and support those entering the profession, giving them the opportunity to discuss their training, development, career progression and self-care with trained professionals who were once in their shoes."
To find out more and to sign up for the Leg Up programme visit https://www.beva.org.uk/Careers/Leg-Up
Interestingly, the survey of 2000 people found that men were 11% more likely than women to change their veterinary surgery if they didn't like the look of the masks. There were also geographical variations in the levels of concern about masks, with Londoners (48%) and people from the South West (46%), the North East (41%) and the West Midlands (41%) being most concerned.
Still, there is some consolation for any practice that is using sub standard masks: 78% of UK adults wouldn’t know how to tell if a face mask was fake.
However, 26% of respondents said they would ask their vet to prove their medical grade face mask meets the certified standard and 22% of pet owners said they would expect their vet to wear a medical grade face mask during routine checkups for the foreseeable future.
James Kinsella, Director at Bluetree Group, said: “During such an unprecedented time, it’s no surprise that people are worried about the use of face masks. It is clear that the public has strong feelings about the quality of face masks in practices, with a third of pet owners saying they are worried about the standard of their vet’s face mask. It’s encouraging to see that where expectations are not met, people will seek an alternative.
"The majority of people admit they would not be able to identify a fake face mask, however it is encouraging that a third of those we spoke to would have the confidence to take action and change their vet if they didn’t think their face mask was up to standard."
For more information on Bluetree Group’s face masks, visit: https://bluetreemaskbox.co.uk.
Consistent with previous surveys, lameness was shown to be more likely to be caused by conditions such as osteoarthritis in the limb rather than problems in the foot.
Blue Cross carries out NEHS in May each year in partnership with the British Equine Veterinary Association (BEVA). It is sponsored by Dodson & Horrell and Zoetis and supported by the UK’s leading equestrian organisations and charities.
This year saw a 14% increase in participation compared to 2015, with survey records returned for almost 16,751 horses, ponies, donkeys and mules and 5635 people taking part. Most horses were kept in livery or a private yard and used for leisure and hacking.
Lameness has been consistently seen as the most common syndrome affecting horses in the NEHS results year on year. In the latest survey a total of 32.9% (24.4% in 2015) of horses and ponies with health problems were recorded as lame. Overall, as in previous years, lameness in the limb was more common than lameness caused by problems in the foot.
A breakdown of the types of lameness revealed that 47.4% were recorded as suffering from proximal limb lameness, 31.9% from causes of foot lameness other than laminitis and 20.7% from laminitis. Degenerative joint disease (including foot and proximal limb) was the most frequently reported single cause of lameness (41.2% of all lameness) and the most frequently reported joint affected by DJD was the hock (15.3% of all lameness).
Reports of foot lameness (excluding laminitis) more than doubled this year at 10.5% (4.5% in 2015) of all syndromes reported with pus in the foot being the most frequently recorded problem. This could possibly be attributed to the persistent wet weather during and prior to the survey, which can increase susceptibility to the condition.
Josh Slater from the Royal Veterinary College, who is a member of BEVA’s Health & Medicines Committee and analysed the NEHS data, said: "The data gleaned from the survey remains consistent year on year, confirming the reliability of our findings for benchmarking, referencing and research. This year’s increase in overall lameness may be in part attributed to the higher incidence of pus in the foot but may also be because owners are becoming more aware of lameness issues. Ongoing research on lameness has generated significant media coverage over the past year, helping to raise understanding of the importance of accurate diagnosis and treatment both from welfare and performance perspectives."
The six most notable disease syndromes identified in the 2016 National Equine Health Survey are:
Gemma Taylor, Education Officer at Blue Cross said: "The significant increase in participation again this year shows that owners and keepers of horses are really getting behind the survey and recognising its importance in safeguarding the future health and of the UK’s horses. Over the past year NEHS data has been referred to in leading equestrian and veterinary media, showing its credibility as a valuable benchmarking reference."
The 2016 NEHS survey results are now available. To download a copy visit http://www.bluecross.org.uk/nehs2016results and to register for next year’s survey please visit www.bluecross.org.uk/nehs
Intervet/Schering-Plough Animal Health has launched Posatex (1% Orbifloxacin, 0.1% Mometasone Furoate Monohydrate and 0.1% Posaconazole, Otic Suspension), a new once-a-day treatment for otitis externa in dogs.
Posatex combines an antibacterial, an anti-inflammatory and an antifungal medication in one, seven-day treatment which the company describes as the 'next generation' treatment for severe otitis externa in dogs, designed to make compliance easier and bring fast relief to dogs suffering from this painful condition.
Allan Weingarten, Director, Pharmaceutical Research, and Posatex R&D Project Leader, said: "As every dog owner knows, this is a 'nightmare' disease. As experts in otic products, we feel a special responsibility to keep improving medications and continuing to make the course of treatment more effective, quicker and easier for both dogs and their caregivers. The novel triazole antifungal posaconazole, new to animal health, is the latest example of innovation in this product area."
Posatex Otic Suspension, available in 7.5, 15 and 30g plastic bottles, is indicated for the treatment of otitis externa associated with susceptible strains of yeast (Malassezia pachydermatis) and bacteria (coagulase positive staphylococci, Pseudomonas aeruginosa and Enterococcus faecalis).
According to the company, posaconazole, the newest element in the three-in-one combination, has been shown to be particularly effective against Malassezia pachydermatis and more potent than other veterinary antifungals. Mometasone furoate monohydrate is a potent and safe anti-inflammatory and Orbifloxacin is a broad-spectrum antibiotic with proven efficacy against bacteria.
Dechra Veterinary Products has launched an online CPD programme to help the veterinary profession diagnose, manage and treat dogs suffering from Hyperadrenocorticism (Cushing's syndrome).
The new Canine Hyperadrenocorticism CPD module has been designed to help vets by providing them with a comprehensive overview of the condition, which they can study in their own time and at their own pace. According to Dechra, it aims to take the guesswork out of managing this complex condition and to support vets in improving the quality of life of Cushing's syndrome patients.
It is the latest online CPD course to be offered through The Dechra Academy, a resource which offers a range of learning and support content and client materials. Accounting for six hours' CPD, the Cushing's syndrome online module complements a CPD road show on the disease recently completed by Dechra around the UK. Over 350 vets attended the sessions and further meetings are scheduled for later in 2011.
Greg Williams, Veterinary Technical Services Manager, said: "Cushing's syndrome remains a challenge to the profession because the clinical signs can easily be confused with those of other disorders and tests results are not always clear cut. We know from the strong attendance at our road show earlier this year that there is a real hunger in the profession to build stronger understanding of the disease.
"Through The Dechra Academy, we bring together the latest thinking on a range of clinical conditions and provide practical, up to the minute training, tips, tools and case studies to help vets spread best practice across their clinical and nursing staff. We also offer CPD in a range of formats - face to face, online and video - to ensure we can accommodate the needs of even the busiest practice.
"We're delighted to launch this new module on Cushing's syndrome and know that it will prove to be a useful tool for vets in practice."
For further information on The Dechra Academy or Cushing's syndrome CPD, please contact your Territory Manager, ring Dechra on 01939 211200 or visit www.dechra.co.uk/academy.
Dechra Veterinary Products Ltd is part of Dechra Pharmaceuticals PLC ('Dechra') and offers a range of pharmaceutical products and instruments to veterinary practices in the UK. The company specialises in the development and marketing of licensed branded pharmaceuticals and specialist premium pet foods for companion animals in the global veterinary market. Dechra is committed to developing new products and services that support the work of veterinary professionals and enhance the lives of their patients and also to investing in products and added-value services that deliver its promise to support veterinary professionals and pet owners.
The practice says that because thiamine deficiency in cats is generally rare, the number of recent cases seen in the UK has been a cause for concern amongst veterinary surgeons.
Symptoms may include severe weight loss or anorexia, vomiting, impaired vision, dilated pupils, tremors and seizures. Prompt treatment is needed, usually in the form of thiamine injections, an oral supplement and an immediate change of food as a precaution.
Laurent Garosi RCVS & European Veterinary Specialist in Neurology at Davies Veterinary Specialists said: "In 20 years I have only seen a handful of cases. My concern is that there may be many more cats out there in need of a diagnosis which is why we are building awareness and supporting our referring vets in the diagnosis of this condition."
To that end, Laurent posted on the subject on Facebook, which immediately went viral, with more than 1.1 million people reached and 9000+ shares.
Davies Veterinary Specialists has followed Laurent's post with support and advice for pet owners, explaining the symptoms to look out for and the emergency measures to take. The practice has also sent more detailed information direct to its referring practices:
What are the signs of thiamine deficiency in cats? Initially most cats will show anorexia and some degree of vomiting preceding neurological signs which include fairly rapid onset of impaired vision, dilated pupils, ataxia, vestibular signs, tremors and seizures.
How do you diagnose thiamine deficiency? It is based on a combination of factors: clinical presentation, MRI findings, which are fairly typical (although not pathognomonic) and response to thiamine supplementation. Absolute confirmation is technically difficult and not widely available: direct measurement of thiamine in the blood may not reflect deficiency, as this is not a good reflection of tissue concentration of Thiamine. Indirect methods are functional tests looking at effects of thiamine or lack of it: demonstration of reduced transketolase activity in red blood cells which is not readily available for most veterinary practices, or other indirect methods such measuring abnormal metabolites such as organic acids in the urine.
What are the causes of thiamine deficiency in dogs and cats? There are three main causes: 1) inability to absorb thiamine due to gastro-intestinal disease, 2) inability to process thiamine due to liver disease and 3) decreased level of thiamine in food. The latter can be caused by the heating process used for food preparation (thiamine is destroyed by heat), addition of sulphur dioxide or sulphite preservatives to meat which inactivate thiamine and feeding food rich in thiaminase activity such as some raw fish. Therefore all-raw fish diet in cats can be a cause of thiamine deficiency.
What to do if you suspect you have a cat with thiamine deficiency and whose diet consists of a product being recalled? Unless the cat is showing neurological signs, the first step is to stop the diet and switch to another diet not listed in the recall. Thiamine supplementation (intramuscular injection) is advised in the first instance in a case with compatible neurological signs. Other causes for the neurological signs must be considered in the case of failing to respond to Thiamine injections within 24-48 hours.
DVS says it is working closely with their referring vets to raise awareness and diagnose any affected animals.
For more information, visit: www.vetspecialists.co.uk and www.facebook.com/DVSvets/